The three Rs in the pharmaceutical industry: Perspectives of scientists and regulators

Animal Welfare

Volumn 14, Issue 4, 2005, Pages 367-377

  Fenwick, N P ^a   Fraser, D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Animal welfare; Drug development; In vitro methods; Pharmaceutical industry; Three Rs; toxicology

Indexed keywords

ANIMAL TESTING ALTERNATIVE; ANIMAL TESTING REDUCTION; ANIMAL TESTING REFINEMENT; ANIMAL TESTING REPLACEMENT; ANIMAL USE; CONTROLLED STUDY; DEATH; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; EXPERIMENTAL ANIMAL WELFARE; GENE EXPRESSION; GENITAL SYSTEM DISEASE; HUMAN; IN VITRO STUDY; INTERVIEW; PHENOTYPE; REVIEW; SAFETY; STATISTICAL ANALYSIS; TRANSGENIC ANIMAL; VALIDATION PROCESS;

ANIMALIA;

EID: 27844438458     PISSN: 09627286     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Balls M 1994 Replacement of animal procedures: alternatives in research, education and testing. Laboratory Animals 28: 193-211
2. Balls M 2002 Future improvements: replacement in vitro methods. Institute for Laboratory Animal Research Journal 43, Suppl: S69-S73
3. Balls M, Combes R, Clothier R, Festing M, Halder M, Jukes N and Morton D 2003 Some reflections on the Fourth World Congress on Alternatives and Animal Use in the Life Sciences. New Orleans, Louisiana, 2002. Journal of Applied Animal Welfare Science 6: 131-149
4. Balls M, Goldberg AM, Fentem JH, Broadhead CL, Burch RL, Festing MFW, Frazier JM, Hendriksen CFM, Jennings M, van der Kamp MDO, Morton D, Rowan AN, Russell C, Spielmann H, Stephens ML, Stokes WS, Straughan D, Yager JD, Zurlo J and van Zutphen BFM 1995 The Three Rs: the way forward. The report and recommendations of ECVAM Workshop II. Alternatives to Laboratory Animals 23: 838-866
5. Balls M, van Zeller A-M and Halder ME 2000 Background to the Three Rs declaration of Bologna, as adopted by the Third World Congress on Alternatives and Animal Use in the Life Sciences. Bologna, Italy, 1999. In: Balls M, van Zeller A-M and Halder ME (eds) Progress in the Reduction, Refinement and Replacement of Animal Experimentation. Proceedings of the 3rd World Congress on Alternatives and Animal Use in the Life Sciences pp 17-22. Elsevier Sciences BV: Amsterdam, The Netherlands
6. Broadhead CL, Betton G, Combes R, Damment S, Everett D, Garner C, Godsafe Z, Healing G, Heywood R, Jennings M, Lumley C, Oliver G, Smith D, Straughan D, Topham J, Wallis R, Wilson S and Buckley P 2000 Prospects for reducing and refining the use of dogs in the regulatory toxicity testing of pharmaceuticals. Human & Experimental Toxicology 19: 440-447
7. Buehr M, Hjorth JP, Hansen AK and Sandøe P 2003 Genetically modified laboratory animals - what welfare problems do they face? Journal of Applied Animal Welfare Science 6: 319-338
8. Burki K 1995 Prospectives of transgenic animals for the pharmaceutical industry. In: van Zutphen LFM and van der Meer M (eds) Welfare Aspects of Transgenic Animals, Proceedings of EC-Workshop pp 48-57. Springer: Berlin, Germany
9. CCAC 1989 Ethics of Animal Investigation. http://www.ccac.ca/en/CCAC_Programs/Guidelines_Policies/POLICIES/ ETHICS.HTM (accessed 22 May 2005)
10. Clark DG 1994 Barriers to the acceptance of in vitro alternatives. Toxicology In Vitro 8: 907-909
11. Coffey A and Atkinson P 1996 Concepts and coding. In: Coffey A and Atkinson P (eds) Making Sense of Qualitative Data: Complementary Research Strategies pp 26-53. SAGE Publications: Thousand Oaks, USA
12. Combes R, Schechtman LM, Stokes WS and Blakey D 2002 The International Symposium on Regulatory Testing and Animal Welfare. Recommendations on best scientific practices for subchronic/chronic toxicity and carcinogenicity testing. Institute for Laboratory Animal Research Journal 43, Suppl: S112-S117
13. Eli Lilly and Company 2004 Animal Care and Use Policy. http://www.lilly.com/about/policies (accessed 17 March 2004)
14. Festing MFW 1994 Reduction of animal use: experimental design and quality of experiments. Laboratory Animals 28: 212-221
15. Festing MFW, Baumanns V, Combes RD, Halder M, Hendriksen CFM, Howard BR, Lovell DP, Moore GJ, Overend P and Wilson MS 1998 Reducing the use of laboratory animals in biomedical research: problems and possible solutions. The report and recommendations of ECVAM Workshop 29. Alternatives to Laboratory Animals 26: 283-301
16. Gad SC and Chengelis CP 1995 Human health products: drugs and medical devices. In: Chengelis CP, Holson JF and Gad SC (eds) Regulatory Toxicology pp 9-49. Raven Press Ltd: New York, USA
17. Glaxo Smith Kline 2001 Care and Ethical Use of Animals. http://science.gsk.com/about/animal-care.htm (accessed 12 August 2004)
18. Harris S 2001 Transgenic knock-outs as part of high-throughput, evidence-based target selection and validation strategies. Drug Discovery Today 6: 628-636
19. ICCVAM 2005 Overview. http://iccvam.niehs.nih.gov/about/overview.htm (accessed 27 July 2005)
20. ICH 1994 Guideline for Industry. Detection of Toxicity to Reproduction for Medicinal Products. http://www.fda.gov/cder/guidance/s5a.pdf (accessed 20 November 2004)
21. ICH 1997 Guidance for Industry: M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. http://www.fda.gov/cder/guidance/1855fnl.pdf (accessed 19 February 2004)
22. Jegstrup I, Thon R, Hansen AK and Ritskes Hoitinga M 2003 Characterization of transgenic mice - a comparison of protocols for welfare evaluation and phenotypic characterization of mice with a suggestion on a future certificate of instruction. Laboratory Animals 37: 1-9
23. O'Connor AM 1997 Barriers to regulatory acceptance. In: van Zutphen LFM and Balls M (eds) Animal Alternatives, Welfare and Ethics. Elsevier Science BV: Amsterdam, The Netherlands
24. Olson H, Graham B, Robinson DE, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B and Heller A 2000 Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology 32: 56-67
25. Pfizer 2002 Laboratory Animal Care and Use. http://www.pfizer.com/are/about_public/mn_about_laboratory_use.html (accessed 12 August 2004)
26. Richmond J 2002 Refinement, reduction and replacement of animal use for regulatory testing: future improvements and implementation within the regulatory framework. Institute for Laboratory Animal Research Journal 43, Suppl. S63-S68
27. Robinson DE and MacDonald JS 2001 Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. Toxicologic Pathology 29: 13-19
28. Rollin BE 2003 Toxicology and new social ethics for animals. Toxicologic Pathology 31: 128-131
29. Russell WMS and Burch RL 1959 (reprinted 1992) The Principles of Humane Experimental Technique. Universities Federation for Animal Welfare: Wheathampstead, UK
30. Schechtman LM 2002 The safety assessment process-setting the scene: an FDA perspective. Institute for Laboratory Animal Research Journal 43, Suppl: S5-S10
31. Schuppli CA, Fraser D and McDonald M 2004 Expanding the Three Rs to meet new challenges in humane animal experimentation. Alternatives to Laboratory Animals 32: 525-532
32. Snodin DJ 2002 An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology. Toxicology Letters 127: 161-168
33. Stephens ML, Conlee K, Alvino G and Rowan AN 2002 Possibilities for refinement and reduction: future improvements within regulatory testing. Institute for Laboratory Animal Research Journal 43, Suppl: S74-S79
34. Stephens ML, Goldberg AM and Rowan AN 2001 The first forty years of the alternatives approach: refining, reducing, and replacing the use of laboratory animals. In: Salem DJ and Rowan AN (eds) The State of the Animals: 2001 pp 121-135. Humane Society Press: Washington DC, USA
35. Stokes WS 2002 Humane endpoints for laboratory animals used in regulatory testing. Institute for Laboratory Animal Research Journal 43, Suppl: S31-S38
36. Tweats D 2000 A review of reduction and refinement of regulatory toxicity studies for pharmaceuticals. In: Balls M, van Zeller AM and Halder ME (eds) Progress in the Reduction, Refinement and Replacement of Animal Experimentation. Proceedings of the Third World Congress on Alternatives and Animal Use in the Life Sciences pp 783-791. Elsevier Science BV: Amsterdam, The Netherlands
37. United States Food and Drug Administration 1992 Animal Testing. http://vm.cfsan.fda.gov/~dms/cos-205.html (accessed 26 January 2004)
38. United States Food and Drug Administration 1996 Guidance for Industry: Single Dose Acute Toxicity Testing for Pharmaceuticals. http://www.fda.gov/cder/guidance/ptl.pdf (accessed 18 February 2004)
39. World Medical Association 1964 Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/e/policy/b3.htm (accessed 13 September 2004)
40. Zurlo J 2000 Obstacles to acceptance and implementation of the Three Rs by scientists. In: Balls M, van Zeller A-M and Halder ME (eds) Progress in the Reduction, Refinement and Replacement of Animal Experimentation. Proceedings of the Third World Congress on Alternatives and Animal Use in the Life Sciences pp 1383-1387. Elsevier Science BV: Amsterdam, The Netherlands